Human chronic chagasic cardiopathy: participation of parasite antigens, subsets of lymphocytes, cytokines and microvascular abnormalities

This article tries to demonstrate by new pathological findings (with the use of immunohistochemical technique and confocal laser microscopy) that chronic chagasic cardiomyopathy is a result of multiple factors involving myocarditis, immunodepression, severe fibrosis and microvessels dilatation and that all of these alterations are probably directly related with the presence of Trypanosoma cruzi parasites in the host associated with inadequate immunological response of the host.

Integrate Study of a Bolivian Population Infected by Trypanosoma cruzi, the Agent of Chagas Disease

A cross section of a human population (501 individuals) selected at random, and living in a Bolivian community, highly endemic for Chagas disease, was investigated combining together clinical, parasitological and molecular approaches. Conventional serology and polymerase chain reaction (PCR) indicated an active transmission of the infection, a high seroprevalence (43.3%) ranging from around 12% in < 5 years to 94.7% in > 45 years, and a high sensitivity (83.8%) and specificity of PCR. Abnormal ECG tracing was predominant in chagasic patients and was already present among individuals younger than 13 years. SAPA (shed acute phase antigen) recombinant protein and the synthetic peptide R-13 were used as antigens in ELISA tests. The reactivity of SAPA was strongly associated to Trypanosoma cruzi infection and independent of the age of the patients but was not suitable neither for universal serodiagnosis nor for discrimination of specific phases of Chagas infection. Anti-R-13 response was observed in 27.5% only in chagasic patients. Moreover, anti-R13 reactivity was associated with early infection and not to cardiac pathology. This result questioned previous studies, which considered the anti-R-13 response as a marker of chronic Chagas heart disease. The major clonets 20 and 39 (belonging to Trypanosoma cruzi I and T. cruzi II respectively) which circulate in equal proportions in vectors of the studied area, were identified in patients' blood by PCR. Clonet 39 was selected over clonet 20 in the circulation whatever the age of the patient. The only factor related to strain detected in patients' blood, was the anti-R-13 reactivity: 37% of the patients infected by clonet 39 (94 cases) had anti-R13 antibodies contrasting with only 6% of the patients without clonet 39 (16 cases).

High prevalence anti-Trypanosoma cruzi antibodies, among blood donors in the State of Puebla, a non-endemic area of Mexico

Blood transfusion is the second most common transmission route of Chagas disease in many Latin American countries. In Mexico, the prevalence of Chagas disease and impact of transfusion of Trypanosoma cruzi-contaminated blood is not clear. We determined the seropositivity to T. cruzi in a representative random sample, of 2,140 blood donors (1,423 men and 647 women, aged 19-65 years), from a non-endemic state of almost 5 millions of inhabitants by the indirect hemagglutination (IHA) and enzyme linked immunosorbent assay (ELISA) tests using one autochthonous antigen from T. cruzi parasites, which were genetically characterized like TBAR/ME/1997/RyC-V1 (T. cruzi I) isolated from a Triatoma barberi specimen collected in the same locality. The seropositivity was up to 8.5% and 9% with IHA and ELISA tests, respectively, and up to 7.7% using both tests in common. We found high seroprevalence in a non-endemic area of Mexico, comparable to endemic countries where the disease occurs, e.g. Brazil (0.7%), Bolivia (13.7%) and Argentina (3.5%). The highest values observed in samples from urban areas, associated to continuous rural emigration and the absence of control in blood donors, suggest unsuspected high risk of transmission of T. cruzi, higher than those reported for infections by blood e.g. hepatitis (0.1%) and AIDS (0.1%) in the same region.

Antibody isotype responses in Balb/c mice immunized with the cytoplasmic repetitive antigen and flagellar repetitive antigen of Trypanosoma cruzi

In the present report we analyzed the levels of IgG1, IgG2a, IgG2b and IgG3 isotypes from Balb/c mice immunized with cytoplasmic repetitive antigen (CRA), and flagelar repetitive antigen (FRA) of Trypanosoma cruzi. The immunization was done by subcutaneous route three times (20 days apart) and the analysis was performed 14 days after each treatment. CRA-immunized mice produced high levels of all IgG isotypes, mainly IgG3 and IgG1. FRA-immunization elicited only high levels of IgG1.

Analysis of expressed sequence tags from Trypanosoma cruzi amastigotes

A total of 880 expressed sequence tags (EST) originated from clones randomly selected from a Trypanosoma cruzi amastigote cDNA library have been analyzed. Of these, 40% (355 ESTs) have been identified by similarity to sequences in public databases and classified according to functional categorization of their putative products. About 11% of the mRNAs expressed in amastigotes are related to the translational machinery, and a large number of them (9% of the total number of clones in the library) encode ribosomal proteins. A comparative analysis with a previous study, where clones from the same library were selected using sera from patients with Chagas disease, revealed that ribosomal proteins also represent the largest class of antigen coding genes expressed in amastigotes (54% of all immunoselected clones). However, although more than thirty classes of ribosomal proteins were identified by EST analysis, the results of the immunoscreening indicated that only a particular subset of them contains major antigenic determinants recognized by antibodies from Chagas disease patients.

Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection

In our laboratory, we have developed a model of vaccination in mice with Trypanosoma rangeli, a non-pathogenic parasite that shares many antigens with Trypanosoma cruzi. The vaccinated mice were protected against infection with virulent T. cruzi. The goal of the present work was to study the protective activity of strains of T. rangeli of different origin, with the aim of analysing whether this protective capacity is a common feature of T. rangeli. BALB/c mice were vaccinated with live or fixed epimastigotes of two T. rangeli strains, Choachi and SC-58. Vaccinated (VM) and control mice (CM) were infected with virulent T. cruzi, Tulahuen strain. The results showed that the levels of parasitemia of VM, vaccinated with the two strains of T. rangeli were significantly lower than those developed in CM. The survival rate of VM was higher than that CM. Histological studies revealed many amastigote nests and severe inflammatory infiltrates in the heart and skeletal muscles of CM, whereas in the VM only moderate lymphomonocytic infiltrates were detected. Altogether, the results of the present work as well as previous studies show that the antigens involved in the protection induced by T. rangeli are expressed in different strains of this parasite. These findings could prove useful in vaccine preparation.

The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives

In previous work, we proposed alternative protocols for following patients with treated Chagas disease and these are reviewed herein. Evidence was provided to support the following: (i) functional anti-trypomastigote antibodies are indicative of ongoing chronic Trypanosoma cruzi infections; (ii) specific antibodies detected by conventional serology (CS) with epimastigote extracts, fixed trypomastigotes or other parasite antigens may circulate years after parasite elimination; (iii) functional antibodies are evidenced by complement-mediated lysis of freshly isolated trypomastigotes, a test which is 100% specific, highly sensitive, and the first to revert after T. cruzi elimination and (iv) the parasite target for the lytic antibodies is a glycoprotein of high molecular weight (gp160) anchored at the parasite surface. The complement regulatory protein has been cloned, sequenced and produced as a recombinant protein by other groups and is useful for identifying functional anti-T. cruzi antibodies in ELISA tests, thus dispensing with the need for live trypomastigotes to manage treated patients. If used instead of CS to define cures for Chagas patients, ELISA will avoid unnecessary delays in finding anti-T. cruzi drugs. Other highly sensitive techniques for parasite DNA detection, such as PCR, need to be standardized and included in future protocols for the management of patients with drug-treated Chagas disease.

Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice

Vaccines have had an unquestionable impact on public health during the last century. The most likely reason for the success of vaccines is the robust protective properties of specific antibodies. However, antibodies exert a strong selective pressure and many microorganisms, such as the obligatory intracellular parasite Trypanosoma cruzi, have been selected to survive in their presence. Although the host develops a strong immune response to T. cruzi, they do not clear the infection and instead progress to the chronic phase of the disease. Parasite persistence during the chronic phase of infection is now considered the main factor contributing to the chronic symptoms of the disease. Based on this finding, containment of parasite growth and survival may be one method to avoid the immunopathology of the chronic phase. In this context, vaccinologists have looked over the past 20 years for other immune effector mechanisms that could eliminate these antibody-resistant pathogens. We and others have tested the hypothesis that non-antibody-mediated cellular immune responses (CD4+ Th1 and CD8+ Tc1 cells) to specific parasite antigens/genes expressed by T. cruzi could indeed be used for the purpose of vaccination. This hypothesis was confirmed in different mouse models, indicating a possible path for vaccine development.

Trypanosoma cruzi infection: a continuous invader-host cell cross talk with participation of extracellular matrix and adhesion and chemoattractant molecules

Several lines of evidence have shown that Trypanosoma cruzi interacts with host extracellular matrix (ECM) components producing breakdown products that play an important role in parasite mobilization and infectivity. Parasite-released antigens also modulate ECM expression that could participate in cell-cell and/or cell-parasite interactions. Increased expression of ECM components has been described in the cardiac tissue of chronic chagasic patients and diverse target tissues including heart, thymus, central nervous system and skeletal muscle of experimentally T. cruzi-infected mice. ECM components may adsorb parasite antigens and cytokines that could contribute to the establishment and perpetuation of inflammation. Furthermore, T. cruzi-infected mammalian cells produce cytokines and chemokines that not only participate in the control of parasitism but also contribute to the establishment of chronic inflammatory lesions in several target tissues and most frequently lead to severe myocarditis. T. cruzi-driven cytokines and chemokines may also modulate VCAM-1 and ICAM-1 adhesion molecules on endothelial cells of target tissues and play a key role in cell recruitment, especially of activated VLA-4+LFA-1+CD8+ T lymphocytes, resulting in a predominance of this cell population in the inflamed heart, central nervous system and skeletal muscle. The VLA-4+-invading cells are surrounded by a fine network of fibronectin that could contribute to cell anchorage, activation and effector functions. Since persistent "danger signals" triggered by the parasite and its antigens are required for the establishment of inflammation and ECM alterations, therapeutic interventions that control parasitism and selectively modulate cell migration improve ECM abnormalities, paving the way for the development of new therapeutic strategies improving the prognosis of T. cruzi-infected individuals.

Experiências sôbre a transmissão do Trypanosoma cruzi por sanguessugas e de tripanosomas de vertebrados de sangue frio por triatomíneos

Observou-se que o Trypanosoma cruzi não se multiplica na sanguessuga (Haementeria lutzi Pinto); os tripanosomas sugados degeneram após algum tempo; outros permanecem aparentemente normais, porém 48 horas após a ingestão infectante acabam morrendo. Observou-se ainda que os tripanosomas parasitas da rã (T. rotatorium e T. leptodactyli) bem como o T. hogei, parasita da serpente Rachidelus brazili, não se multiplicam no intestino dos triatomíneos. O mais resistente (o T. leptodactyli), permanece vivo até 72 horas após a ingestão infectante, porém as outras duas espécies (T. rotatorium e T. hogei) não resistem mais de 24 horas após serem sugadas pelos triatomíneos.

Esterilidad individual en Rhodnius prolixus Stal. tratados con metepa (oxido de tris (1-(2 metil) aziridinil) fosfuro), y accion del mismo sobre Trypanosoma cruzi

Se analizan los factores que interfieren en la esterilidad inducida químicamente en R. Prolixus mediante aplicaciones tópicas en distintas dosis de metepa. Se sugiere profundizar el estudio de la susceptibilidad individual para conocer la composición de la población frente al quimioesterilizante y la probable aparición de resistencia. Se investiga además la acción del metepa sobre T. cruzi en triatominos infectados experimentalmente, obteniéndose resultados negativos.

Nota sobre a infecção natural de Calomys expulsus, Lund, 1841 (Cricetidae-Rodentia) pelo Trypanosoma cruzi

Foi isolada uma amostra de T. cruzi do roedor silvestre, Calomys expulsus, Lund, 1841, capturado no norte do município de Formosa, Goiás, através de inoculações em animais de laboratório, e subseqüente xenodiagnósticos com R. neglectus, T. infestans e P. megistus. A amostra de T. cruzi apresentou patogenicidade muito baixa para os animais inoculados, mas conferiu resistência a reinjecções a cêpa Y de origem humana. As jornias sanguícolas tiveram um comprimento total médio de 21.8 µ e o índice nuclear foi 1.15.

Prevalência da infecção por Trypanosoma cruzi, em 1975, em dois bancos de sangue de Londrina, Paraná, Brasil

Foi realizado inquérito sobre a positividade de reações sorológicas para o diagnóstico de tripanossomíase americana, em 4.500 candidatos a doadores não selecionados, atendidos em 1975, em dois bancos de sangue de Londrina, Paraná, Brasil. Observou-se resultado positivo da reação de fixação do complemento em 299 (7,9%) dos 3.774 candidatos a doadores atendidos no Banco de Sangue do Hospital Universitário (indivíduos residentes predominantemente na zona rural), tendo também sido positivos os resultados da reação de fixação do complemento e do teste de imunofluorescência indireta em 38 (5,2%) dos 726 candidatos a doadores atendidos no Instituto de Hematologia e Hemoterapia (indivíduos residentes predominantemente na zona urbana). Na casuística global a positividade observada foi de 7,4%. Dentre os 337 candidatos a doadores com reação sorológica positiva, 97 (28,7%) informaram ter doado sangue anteriormente, em outro local, 71 (21,0%) dos quais em período prévio menor que um ano, e 42 (12,4%) em período prévio menor que seis meses, em relação à data do nosso exame. Comparando os dados obtidos nesta avaliação com os de inquéritos semelhantes efetuados em 1958 em bancos de sangue deste município, concluiu-se que não houve, nesse período, alteração significativa nos índices de infecção por Trypanosoma cruzi em Londrina. Chamam a atenção para a discrepância entre o reduzido número de casos de doença de Chagas pós-transfusional relatados na literatura e os altos índices de positividade de reações sorológicas para o diagnóstico de tripanossomíase americana registrados em bancos de sangue de diversas regiões do Brasil. Foi ressaltada, a importância de exigir-se maior rigor e parcimônia nas indicações de transfusões de sangue, e dada ênfase às normas que devem ser respeitadas quando o uso desse recurso terapêutico tiver indicação formal.

Alguns aspectos do comportamento de cepas silvestres de Trypanosoma cruzi em camundongos e Calomys callosus (Rodentia)

Foram estudadas quatro cepas silvestres de T. cruzi: M226 isolada de Calomys callosus (Rodentia) e R52, R64 e R65 isoladas de Didelphis albiventris (Marsupialia). Estes animais foram coletados no município de Formosa, Goiás, Brasil. Os aspectos abordados, relacionados com o comportamento destas cepas em camundongos "swiss" 40 e C. callosus nascidos em laboratório, foram: parasitemia, prepatência, letalidade e histopatologia. Os resultados indicaram que as quatro cepas tinham baixa virulência para os animais testados. A parasitemia sempre se apresentou baixa e regular para os C. callosus. Nos camundongos, só raramente a parasitemia era patente. A prepatência nos C. callosus variou em média entre 9,2 a 10,2 dias, enquanto nos camundongos ficou entre 12-48 dias. A letalidade para C. callosus foi 7,7% e para camundongos 12,0%. Os estudos histopatológicos mostraram que somente 17,2% dos C. callosus apresentaram parasitismo tissular, enquanto em 25% dos camundongos foram encontrados pseudocistos íntegros ou rompidos. Houve um nítido miotropismo das quatro cepas tanto nos camundongos quanto nos C. callosus.

Crescimento e diferenciação "In vitro" de cepas de Trypanosoma cruzi, isoladas de animais silvestres

Foram estudadas três cepas de T. cruzi isoladas de Didelphis albiventris (R52, R64 e R65) e uma isolada de Calomys callosus (M226), quanto ao comportamento "In vitro" no meio LIT. A evolução da população dos tripanossomas com relação ao crescimento e morfogênese foi acompanhada por um período de 13 dias (312 horas), em intervalos regulares. As contagens diferenciais, separando-se formas amastigotas, epimastigotas e tripomastigotas, foram realizadas na câmara de Neubauer. Os resultados obtidos levaram à conclusão de que as 4 cepas estudadas têm comportamento distintos. O melhor crescimento obtido ocorreu para a cepa M226, seguindo-se por ordem decrescente a R65, R52 e R64. Os picos das populações ocorreram como segue: M226, entre 192-264 horas; R65 entre 168-240 horas; R52 às 240 horas e R64 entre 264-312 horas.